[illegible]

# HUA MEDICINE
# 華領醫藥

*(I[illegible] C[illegible] I[illegible])*

**(stock code: 2552)**

## VOLUNTARY ANNOUNCEMENT – UPDATE REGARDING RECENT BUSINESS DEVELOPMENTS HUA MEDICINE ANNOUNCES ADDITIONAL DATA IN -CELL FUNCTION

T[illegible] H[illegible] M[illegible] ([illegible] **Company**[illegible] **Group**) [illegible] C[illegible] G[illegible].

T[illegible] DAWN [illegible] C[illegible] D[illegible] S[illegible] 2020 S[illegible] M[illegible]:

– F[illegible] H[illegible] A1 [illegible] 4 [illegible])

– S[illegible]

– S[illegible] 2-[illegible]

– G[illegible] ([illegible] 1% [illegible] 24-[illegible])

– S[illegible] 24 [illegible]

– G[illegible]

A[illegible] 1 [illegible] C[illegible] N[illegible] 26 2020 C[illegible].

**Cautionary Statement required by Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** The Company's Board of Directors expects that the Company will not be able to publish its annual results for the year ended September 30, 2020 by the end of November 2020 as required by Rule 13.49(1) of the Listing Rules.

By Order of the Board
**Dr. Li Chen**
*Chairman, Executive Director*

Shanghai, China, November 26, 2020

*As of the date hereof, the Board comprises Dr. Li Chen as Chairman and Executive Director; Mr. Ren Tianbo as Non-executive Director; Dr. Li Zhiming, Mr. Wang Ruigang and Mr. Kee Teck Koon as Independent Non-executive Directors; and Mr. Jiang Lihua, Mr. Yang Wenjun and Mr. Tian Suning as Executive Directors.*

**Hua Medicine's Dorzagliatin Announces Additional Data To Presented at the 2020 Chinese Diabetes Society Scientific Meeting**

N... 26, 2020 ... S..., C...

H... M... (... **Company**..., S... C...: 2552.HK), ... 24-... DAWN, (... HMM0302).

F... DAWN ... C... D... S... 2020 S... M... T... 24-... T... 2 ... (1,500 ...), ... H... A1 ... 1.02%, ... 0.66% (... + ... H... A1 ... 0.36%). D... :

– F... H... A1 ... 4 ...)

– S...

– S... 2-...

– G... (... 1% ... 24-... )

– S... 24 ...

– G...

T... D... L... C..., CEO ... CSO ... H... M... T... T... 2 ... T2D ...

I... SGLT-2 ... DPP-4 ...

**In the trial, Dorzagliatin exhibits positive impact on blood glucose control.**

T[illegible] P[illegible] III [illegible] T2D [illegible].

- D[illegible] 1.02% [illegible] H[illegible] A1[illegible] 0.36% [illegible]
- D[illegible] 40% [illegible] 8, [illegible] 44.4% [illegible] 24
- S[illegible] 2-[illegible] (-5.45 [illegible]/L [illegible] -2.98 [illegible]/L, [illegible] <0.0001)
- P[illegible]
- H[illegible] 1% [illegible] 24-[illegible])
- O[illegible]
- T[illegible] HOMA2-[illegible][1] [illegible] 3.77% [illegible] 1.35% [illegible]

*N[illegible] 1:* T[illegible] HOMA, H[illegible] M[illegible] A[illegible] 1985. I[illegible] HOMA2 [illegible] HOMA1 [illegible]

*S[illegible]: D[illegible] C[illegible] 2004, 27(6), 1487*

## About Dorzagliatin

D [illegible] T 2 [illegible] B [illegible] T 2 [illegible] T C [illegible] P III [illegible] P III [illegible] 52- [illegible] 2020. H [illegible] M [illegible] D A [illegible] B [illegible] NDA [illegible] NMPA, [illegible] C [illegible]

## About Hua Medicine

H [illegible] M [illegible] C [illegible] F [illegible] H [illegible] M [illegible] T2DM NDA [illegible] P III [illegible] C [illegible] S [illegible] D [illegible] P III [illegible] C [illegible] 24- [illegible] 52- [illegible] P III [illegible] T C [illegible] H [illegible] M [illegible] C [illegible]

## For more information

H [illegible] M [illegible]

W [illegible]

I [illegible]

E [illegible]

M [illegible]

E [illegible]